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Abstract
Background: Hexokinase-2 (HK2) and Beta2-adrenergic receptor (Beta2AR) are overexpressed in hepatocellular
carcinoma (HCC) tissues and associated with poor prognosis. However, the synergistic effect of HK2 and Beta2AR in
HCC prognosis is not elucidated. The present study aims to investigate the association between HK2 and Beta2AR
expressions in HCC tissues, and to evaluate the synergistic effect of HK2 and Beta2AR in HCC prognosis.
Methods: Immunohistochemistry of HK2 and Beta2AR was performed on 155 paraffin embedded HCC samples
retrieved from the archives of pathology department. Corresponding clinical data and prognostic data were
collected through searching medical record systems, death registration systems and interviews with patient families.
Spearman correlation test was performed to evaluate the association between HK2 and Beta2AR expression.
Kaplan-Meier survival curves and Cox regressions were employed to evaluate HK2 and Beta2AR expression in HCC
prognosis, respectively and synergistically.
Results: 109 of 155 HCC patients reached the death point, the survival time of HCC patients was 46.23 ± 31.
01 months after curative surgical resections of HCC. Kaplan-Meier survival analysis showed that large tumor
size (more than 5 cm) (hazard ratio (HR) = 8.42, 95 % confidence interval (CI) = 3.81–18.59, P < 0.0001),
advanced TNM stage (III and IV stages) (HR = 2.09, 95%CI = 1.21–3.62, P < 0.001) and AFP more than 20 μg/L
(HR = 1.49, 95%CI = 1.02–2.18, P = 0.0302) were predictors for poor prognosis. HK2 and Beta2AR positive
expression was detected in 66 (42.58) and 122 (78.71 %) HCC samples respectively. In univariate analysis,
HK2(+) (HR = 2.70, 95%CI = 1.76–4.15, P < 0.0001) and Beta2AR(+) (HR = 4.61, 96%CI = 3.14–6.76, P < 0.0001) were
associated with poor prognosis. In multivariate analysis, HK2(+) (P < 0.0001) and Beta2AR(+) (P < 0.0001) were
also associated with poor prognosis. HK2(+)/Beta2AR(+) in HCC samples had poorer prognosis compared with
HK2(−)/Beta2AR(−) in both univariate analysis (HR = 4.69, 95%CI = 2.91–7.57, P < 0.0001) and multivariate analysis
(P < 0.0001). HK2(+)/Beta2AR(+) in HCC samples had poorer prognosis compared with HK2(−)/Beta2AR(+) in
both univariate analysis (HR = 1.76, 95%CI = 1.17–2.64, P = 0.003) and multivariate analysis (P = 0.004).
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Conclusion: HK2 and Beta2AR play important roles in HCC progression. HK2 and Beta2AR expression in HCC
is correlated positively. Beta2AR may increase HCC invasion and metastasis in collaboration with HK2. HK2 and
Beta2AR can predict HCC prognosis both independently and synergistically.
Keywords: Hepatocellular carcinoma, Hexokinase-2, Beta2-adrenergic receptor, Prognosis,
Immunohistochemistry
Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer in men and seventh most common cancer
in women worldwide [1]. HCC is also the third most
common cause of death from carcinomas worldwide [1,
2]. Although new treatment modalities for HCC have
been developed in recent years, improvement of the
five-year survival rates mainly relies on diagnosis at early
stages of HCC. Early stage HCC can be treated with
curative surgical resections, radiofrequency ablation, per-
cutaneous ethanol injection and transarterial chemoem-
bolization [2]. Moreover, only curative surgical resection
has the possibility to cure HCC. As for the advanced
stage HCC, although tyrosine kinase inhibitors, such as
Sorafenib and Linifanib have been developed to improve
survival rates, the cure of advanced stage HCC is rarely
achieved [3, 4]. Therefore, how to choose the optimal
therapy for the individual patient in order to maximize
the survival time is of great importance to both clini-
cians and patients. Another issue of importance to clini-
cians and patients is to predict prognosis of HCC
especially for the patients underwent curative HCC re-
sections and for the patients with advanced stage HCC.
Proper prediction of prognosis can guide clinicians to
choose the right therapies and help patients to arrange
the remaining life appropriately. To date, no individual
biomarker can predict prognosis of HCC accurately. The
combination of two or more correlated biomarkers for
HCC prognosis may improve the power of prognosis
predictions of HCC.
Beta2-adrenergic receptor (Beta2AR) is a transmem-
brane G protein-coupled receptor (GPCR), which can
regulate cell proliferation via cyclic adenosine monopho-
sphate and protein kinase A pathways [5]. Beta2AR are
overexpressed in multiple cancers especially in gastro-
intestinal cancers and HCC [6–8]. It has been proved
that Beta2AR agonist can promote DNA synthesis and
beta-blockers can block DNA synthesis in pancreatic
ductal carcinoma cell lines [7]. Selective Beta2AR blockage
can also suppress colorectal cancer growth via EGFR-Akt/
ERK signaling, G1-phase arrest and apoptosis [9].
Through increasing DNA synthesis, accelerating cell cycle
and decreasing apoptosis, activation of Beta2AR promotes
cancer growth, invasion and metastasis. High expression
of Beta2AR may play a role in the canceration of injured
hepatocytes, and may represent high grade of malignancy
of HCC. So high expression of Beta2AR in HCC tissues is
proposed be a biomarker for poor prognosis, which is sup-
ported by a previous survival study of HCC with immuno-
histochemistry [10].
Besides increased DNA synthesis, accelerated cell cycle
and decreased apoptosis, another feature of cancer is the
energy shift to aerobic glycolysis called Warburg effect,
even in adequate oxygen environments [11]. Accelerated
aerobic glycolysis is of importance to cancer cell sur-
vival, growth and metastasis [11]. Hexokinase (HK) is a
key enzyme in glycolysis, to date, four HK isoforms were
identified in mammals [12]. It is shown that HK2 is
overexpressed in HCC tissues [13, 14]. Overexpression
of HK2 may also represent high grade of malignancy.
Two survival studies proved this hypothesis, and showed
that high level expression of HK2 was an independent
poor prognostic biomarker for HCC [13, 14].
Moreover, HK2 and Beta2AR are not independent,
they are related in HCC development. Recently, one
study indicates that activation of Beta2AR can promote
HK2 expression, and inhibition of Beta2AR can decrease
HK2 expressions in breast cancer cell lines [15]. It is de-
duced that Beta2AR might increase the grade of malig-
nancy of cancers via promoting HK2 expression.
However, the relationship between Beta2AR and HK2
expression in HCC tissues is not fully elucidated. We
postulate that Beta2AR and HK2 expression in HCC tis-
sues correlates positively; overexpression of HK2 and
beta2AR in HCC can predict prognosis of HCC patients
synergistically; Beta2AR may increase the grade of malig-
nancy of HCC via promoting HK2 expression. In the
current study, we performed immunohistochemistry as-
says to prove the above hypotheses.
Methods
HCC patients and tissue samples
This study is a retrospective study. 160 HCC patients
underwent curative resections between January 2000 and
December 2013 in the First affiliated hospital of Dalian
Medical University were included in our study. Surgical
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treatment selection was mainly based on the Barcelona
Clinic Liver Cancer (BCLC) algorithm [16]. Moreover,
ten HCC patients with regional metastasis underwent
HCC resections and lymph node dissections were also
included into our study. Paraffin embedded pathologic
samples were retrieved from the archives of the Depart-
ment of Pathology. All the tissue sections were evaluated
by experienced pathologist to confirm the diagnosis of
HCC. Cholangiocellular carcinoma and other carcin-
omas of the liver were excluded during pathology evalu-
ation. HCC patients accompanied with other site
carcinomas were also excluded from our study. Because
Beta2AR and HK2 were associated with metabolism,
HCC patients accompanied with metabolic diseases in-
cluding diabetes mellitus and thyroid diseases were also
excluded from our study. This study was approved by
Medical Ethics Committee of First Affiliated Hospital of
Dalian Medical University. Consent was obtained from
all participants (alive HCC patients or relatives of de-
ceased HCC patients).
Survival data and clinical data collection
Clinical and laboratory data of each included patient during
the hospital stay for curative resection were retrieved from
the medical record system of the First Affiliated Hospital of
Dalian Medical University. The computed tomography
(CT) scanning and magnetic resonance images (MRI) of
each patient were collected via Picture Archiving and Com-
munication Systems. The records of operational procedures
and observations during operations were also collected via
medical record system. The CT images, MRI images and
observations during operation were used to evaluate the
tumor size (maximum diameter of the tumor). The survival
data and the death date of each patient were retrieved
through telephone interviews with patient families, and
confirmed by searching the municipal death registration
system of Dalian (the final collection date was 20th March
2014, the data collection period was limited in two weeks).
Overall survival was used to evaluate HCC patient survival
after surgical curative resections. Paraffin embedded patho-
logic samples of each patient were reevaluated by experi-
enced pathologist to determine the differentiation grade of
HCC according to Edmondson-Steiner histopathologic
grading [17]. The HCC staging evaluation before operation
was based on American Joint Commission on Cancer 7th
edition TNM system [18].
Immunohistochemistry and density scoring
Immunohistochemistry was performed with the MaxVi-
sionTM AP kit (Fuzhou Maixin Biotech. Co., Ltd, Fuzhou,
China) according to the manufacture manuals. HK2 expres-
sion was evaluated with a rabbit anti-human HK2 mono-
clonal antibody (Cell Signaling Technology, Inc., Danvers,
MA, USA) in accordance with the manufacturer’s protocol
with antibody dilution of 1:50. Beta2AR was evaluated
using a rabbit anti-human Beta2AR monoclonal antibody
(Abcam, Cambridge, MA, USA) in accordance with the
manufacturer’s protocol with antibody dilution of 1:50.
Both the intensity and proportion of stained cells in a HCC
section (200×) were inspected and evaluated. Staining in-
tensity was classified with a four grade system: no staining
(0), weak (1), moderate (2), strong (3). The percentage of
positive stained cells was also classified into a four scale sys-
tem: <5 % (0), 5–25 % (1), 26–50 % (2), >50 % (3). All the
scores were based on the mean scores of ten randomly se-
lected fields of tissue sections. The staining intensity score
plus the percentage score made the final score of each sam-
ple (the final score ranged from 0 to 6). If the final score is
more than 3, the sample was determined to be positive.
Otherwise, the sample was determined to be negative.
Statistical analysis
Pearson Chi-square test was used to analyze the associa-
tions between protein expression and clinical data. Survival
time was shown as mean and standard deviation (SD).
One-way ANOVA analysis and least significant difference
(LSD) test were employed to determine the difference of
live time among different groups. Spearman correlation test
was performed to evaluate the association between HK2
and beta2AR expression with the final scores. Kaplan-
Meier survival curve was employed to evaluate HK2 ex-
pression, Beta2AR expression and clinical data in HCC
prognosis, respectively and synergistically. Cox regression
analysis was also performed for multivariate analyses (all
the selected clinical data was included in Cox regression)
for HK2, Beta2AR and clinical data in HCC prognosis. P <
0.05 was considered statistically significant. Pearson Chi-
square test and One-way ANOVA analysis were performed
with the SPSS16.0 statistical software package (SPSS Inc.,
Chicago, IL, USA). Survival analysis and Cox regression
analysis were performed with MedCalc 11.4.2.0 (Med-
Calc Software bvba, Acacialaan, Ostend, Belgium).
Survival curve, Cox regression curve, Spearman cor-
relation diagram and One-way ANOVA diagram were
depicted with MedCalc 11.4.2.0 (MedCalc Software
bvba, Acacialaan, Ostend, Belgium).
Results
The association between clinical data and survival
160 paraffin embedded HCC samples were retrieved
from the archives of pathology department. Complete
clinical data and prognostic data were collected through
searching medical record systems and taking interviews
with patient families. The survival data were confirmed
by searching municipal death registration system of Da-
lian. Survival information of 155 patients was retrieved
successfully, the rate of lost to follow-up was 3.13 %. 155
patients were included into final analyses. 109 (70.32 %)
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HCC patients reached the death point, the survival time
of HCC patients was 46.23 ± 31.01 months after curative
surgical resections of HCC. Kaplan-Meier survival ana-
lysis showed that large tumor size (more than 5 cm)
(hazard ratio (HR) = 8.42, 95 % confidence interval (CI)
= 3.81–18.59, P < 0.0001), advanced TNM stage (III and
IV stages) (HR = 2.09, 95%CI = 1.21–3.62, P < 0.001) and
AFP more than 20ug/L (HR = 1.49, 95%CI = 1.02–2.18,
P = 0.0302) were predictors for poor prognosis. Age,
gender, Hepatitis viral infection, tumor number, tumor
differentiation grade and post operational treatment are
not associated with prognosis of HCC patients. Cox re-
gression showed that only large tumor size and advanced
TNM stage were associated with poor prognosis of HCC
patients.
HK2 and Beta2AR are over expressed in HCC
Positive staining of HK2 was detected in the cytoplasm
of HCC tissues. And positive staining of Beta2AR was
also detected in the membrane and cytoplasm of HCC
Fig. 1 Immunochemistry of HCC tissues. a Representative positive staining of HK2 in HCC tissues. b Representative negative staining of HK2 in
HCC tissues. c Representative positive staining of Beta2AR in HCC tissues. d Representative negative staining of Beta2AR in HCC tissues
Fig. 2 Spearman correlation between HK2 and Beta2AR. Spearman correlation test shows that HK2 and Beta2AR expression is correlated
positively (P < 0.0001)
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tissues. Representative positive staining and negative
staining of HK2 and Beta2AR in HCC tissues are shown in
Fig. 1. According to the scores of staining, HK2 and
Beta2AR positive expression was detected in 66 (42.58) and
122 (78.71 %) HCC samples, respectively. Spearman correl-
ation test showed that HK2 and Beta2AR expression was
correlated positively (P < 0.0001), as shown in Fig. 2.
The association between HK2/Beta2AR expression and
clinical data
There was no significant difference between HK2 positive
staining samples and HK2 negative staining samples in age,
gender, Hepatitis viral infection, AFP level, tumor number,
tumor differentiation grade and post operational treatment.
Only large tumor size and advanced TNM stage were cor-
related with HK2 positive staining positively. There was
also no significant difference between Beta2AR positive
staining samples and Beta2AR negative staining samples in
age, gender, Hepatitis viral infection, AFP level, tumor
number, TNM stage, tumor differentiation grade and post
operational treatment. Only large tumor size was correlated
with Beta2AR positive staining positively. The details of the
association tests between HK2/Beta2AR expression and
clinical data are shown in Tables 1 and 2.
Table 1 The details of association between Beta2AR expression
and clinical data
Beta2AR positive Beta2AR negative P value
Age
≤ 50 year 35 7 0.391




Hepatitis virus infection 0.439
HBV 106 29
HCV 4 2
HBV + HCV 1 1
None 11 1
AFP level 0.685
≤ 20ug/L 58 17





≤ 5 cm 82 33










Post operation treatment 0.483
None 77 23
TACE 45 10
Table 2 The details of association between HK2 expression and
clinical data
HK2 positive HK2 negative P value
Age
≤ 50 year 23 19 0.062




Hepatitis virus infection 0.594
HBV 57 78
HCV 3 3
HBV + HCV 0 2
None 6 6
AFP level 0.054
≤ 20ug/L 26 49





≤ 5 cm 40 75










Post operation treatment 0.630
None 44 56
TACE 22 33
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HK2 and Beta2AR can predict HCC prognosis
independently and synergistically
Positive Beta2AR staining was observed in all HK2 posi-
tive HCC samples. Moreover, when Beta2AR was nega-
tive in the HCC tissues, HK2 was also negative in the
corresponding samples. In the Beta2AR positive staining
HCC tissues, there was no significant difference between
HK2 positive samples and HK2 negative ones in age,
gender, Hepatitis viral infection, AFP level, tumor num-
ber, tumor differentiation grade and post operational
treatment. Only advanced TNM stage was correlated
with HK2 positive staining. The details of the association
tests between HK2 expression and clinical data in
Beta2AR positive samples are shown in Table 3.
In univariate analysis, HK2(+) (HR = 2.70, 95%CI =
1.76–4.15, P < 0.0001) and Beta2AR(+) (HR = 4.61, 96%CI
= 3.14–6.76, P < 0.0001) were associated with poor prog-
nosis. In multivariate analysis, HK2(+) (P < 0.0001) and
Beta2AR(+) (P < 0.0001) were also associated with poor
prognosis. HK2(+)/Beta2AR(+) in HCC samples had
poorer prognosis as compared with HK2(−)/Beta2AR(−)
in both univariate analysis (HR = 4.69, 95%CI = 2.91–7.57,
P < 0.0001) and multivariate analysis (P < 0.0001). HK2(+)/
Beta2AR(+) in HCC samples had the poorer prognosis as
compared with HK2(−)/Beta2AR(+) in both univariate
analysis (HR = 1.76, 95%CI = 1.17–2.64, P = 0.003) and
multivariate analysis (P = 0.004). The survival analysis
curves are shown in Fig. 3.
Regarding patients that reached death point, one-way
ANOVA analysis showed that survival time of HK2(−)/
Beta2AR(−) patients (106.29 ± 26.68 months) was longer
than that of HK2(−)/Beta2AR(+) patients (45.61 ±
19.12 months) (P < 0.0001) and HK2(+)/Beta2AR(+)
patients (31.13 ± 18.00 months) (P < 0.0001) significantly.
The survival time of HK2(−)/Beta2AR(+) patients was
also longer than that of HK2(+)/Beta2AR(+) patients
(P = 0.001). The details of one-way ANOVA analysis
are shown in Fig. 4.
Discussion
HCC is the third most common cause of death from car-
cinomas worldwide [1, 2]. Moreover HCC is also one of
the main causes of death of liver cirrhosis irrespective of
cirrhotic etiology [19]. Due to the increasing incidence
of hepatitis C virus (HCV) infections and non-alcoholic
fatty liver disease (NAFLD), the incidence of HCC in
USA has doubled in the past twenty years. Based on the
trend of HCC incidence, it is postulated that HCC is
likely to replace breast cancer and colorectal cancer to
become the third cause of death from carcinomas in
USA [20]. Different from developed countries, the eti-
ology of HCC in developing countries especially south-
eastern Asian countries is hepatitis B virus (HBV)
infection [21, 22]. The high incidence of HBV infection
also makes HCC to be a big healthy problem in south-
eastern Asian countries. Irrespective of the etiology of
HCC, the prognosis of HCC mainly relies on diagnosis
at early stage and the possibility of curative surgical re-
sections. However, even in USA, the rate of HCC diag-
nosed at early stage is only 46 % [20]. And only a small
portion of HCC patients diagnosed at early stage can re-
ceive curative resections [20]. In the developing coun-
tries, the rates of HCC diagnosed at early stage and the
portions of HCC patients at early stage received curative
resections are very low. Although tyrosine kinase
Table 3 The details of association between HK2 expression and
clinical data in Beta2AR positive samples
Beta2AR positive
HK2 positive HK2 negative P value
Age
≤ 50 year 23 12 0.102




Hepatitis virus infection 0.596
HBV 57 49
HCV 3 1
HBV + HCV 0 1
None 6 5
AFP level 0.050
≤ 20ug/L 26 32





≤ 5 cm 40 42










Post operation treatment 0.377
None 44 33
TACE 22 23
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inhibitors (such as Sorafeniband Linifanib) have been
developed to treat HCC at advanced stage, the out-
come of treatment at advanced stage is not satisfac-
tory [3, 4]. Scientists are still searching for new HCC
treatment targets. Exploring the mechanism of HCC
development may shed light on developing new ther-
apies. Another realistic issue of importance to clini-
cians and patients is to predict prognosis of HCC.
Proper prediction of prognosis can guide clinicians to
choose the right therapies and help patients to ar-
range the remaining life appropriately.
Beta2AR regulates cell proliferation via cyclic adeno-
sine monophosphate and protein kinase A pathways [5].
Through increasing DNA synthesis, accelerating cell
cycle and decreasing apoptosis, activation of Beta2AR
promotes cancer growth, invasion and metastasis. A pre-
vious study indicates that high expression of Beta2AR in
HCC tissues is a biomarker for poor prognosis [10]. The
Fig. 3 Survival curve. a and b HK2(+) is associated with poor prognosis in both univariate analysis (HR = 2.70, 95%CI = 1.76–4.15, P < 0.0001) and
multivariate analysis (P < 0.0001). c and d Beta2AR(+) is associated with poor prognosis in both univariate analysis (HR = 4.61, 96%CI = 3.14–6.76,
P < 0.0001) and multivariate analysis (P < 0.0001). e and f HK2(+)/Beta2AR(+) in HCC samples shows poorer prognosis as compared with HK2(−)/
Beta2AR(−) in both univariate analysis (HR = 4.69, 95%CI = 2.91–7.57, P < 0.0001) and multivariate analysis (P < 0.0001). HK2(+)/Beta2AR(+) in HCC
samples shows poorer prognosis as compared with HK2(−)/Beta2AR(+) in both univariate analysis (HR = 1.76, 95%CI = 1.17–2.64, P = 0.003) and
multivariate analysis (P = 0.004)
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Kaplan-Meier survival analysis and Cox regression ana-
lysis of our study are in consistence with the findings of
this study. Our study also proves that high expression of
Beta2AR in HCC is associated with large tumor size,
which implies high expression Beta2AR in HCC playing
an important role in tumor growth.
Glycolysis is the the key step for cellular energy me-
tabolism, which converts glucose into pyruvate to pro-
duce adenosine triphosphate (ATP) [23]. Ten steps and
corresponding enzymes participate in this process.
Among these enzymes, HK is the first step enzyme con-
verting glucose into glucose 6-phosphate, and pyruvate
kinase (PK) is the final step enzyme converting phospho-
enolpyruvate into pyruvate [23]. When abundant oxygen
is present, pyruvate enters tricarboxylic acid (TCA) cycle
to produce ATP in mitochondria. Under hypoxia condi-
tions, pyruvate will be converted into lactate by lactate
dehydrogenase (LDH) to produce ATP. Tumor prefers
the latter instead of entering the TCA cycle to produce
energy, even under sufficient oxygen conditions, which
is called Warburg effect [11]. HK and PK play important
roles in this energy shift [24]. To date, four HK isoforms
and four PK isoforms are identified in mammals [12, 25,
26]. Different from normal liver cells, HCC tissues ex-
press HK2 and PKM2 predominantly [13, 14, 27]. This
isoform alteration makes cancer cells prefer aerobic gly-
colysis instead of aerobic oxidation [11]. Accelerated aer-
obic glycolysis supplies abundant energy to cancer cells
for their survival, growth and metastasis [11]. HK2 par-
ticipates in tumor initiation and maintenance, and HK2
depletion inhibits the neoplastic phenotype of human
lung and breast cancer cells in vitro and in vivo [25].
Previous study showed that 3-bromopyruvate (3-BP), a
HK2 inhibitor induced apoptosis of HCC cells via aug-
menting ER stress and anti-angiogenesis by protein di-
sulfide isomerase inhibition [28]. In another study,
Resveratrol (a HK2 inhibitor) also induces apoptosis of
HCC cells via inhibiting aerobic glycolysis [29]. All the
above evidence indicates that HK2 might be a potential
therapeutic target for HCC.
Recently one study also revealed that the levels of
HK2 expression in dysplastic cirrhosis and HCC was
higher than that of non dysplastic cirrhosis and normal
liver, which indicates that high expression of HK2 is as-
sociated with high grade of malignancy [30]. Previous
studies also showed that high expression of HK2 was an
independent poor prognostic biomarker for HCC [13,
14]. The results of our study are in consistence with
these two survival studies. Our study also suggests that
high expression of HK2 is associated with large tumor
size and advanced TNM stages, which indicates that
high expression of HK2 in HCC represents high levels of
malignancy. High HK2 expression in HCC tissues can
also be used as a biomarker for poor HCC prognosis.
Moreover, HK2 and Beta2AR are correlated in HCC
development. Previous study indicates that activation of
Beta2AR can promote HK2 expression, and inhibition of
Beta2AR can decrease HK2 expressions in breast cancer
cell lines [15]. Our study also shows positive associations
between HK2 and Beta2AR in HCC tissues. Additionally,
Beta2AR positive staining in HCC is not associated with
TNM stage in our study. However, in Beta2AR positive
stained samples, HK2 positive staining is associated with
TNM stage. This may imply that Beta2AR increases
HCC invasion and metastasis through HK2 activation.
Detecting HK2 and Beta2AR simultaneously may help
clinicians to evaluate the malignant status of HCC.
Combination therapy of targeting HK2 and Beta2AR
might be a promising strategy for HCC.
Combination of HK2 and Beta2AR detection also im-
proves the predictive power for prognosis. The Kaplan-
Meier survival analysis and Cox regression analysis of
our study showed that HK2(+)/Beta2AR(+) HCC pa-
tients had poorer prognosis compared with HK2(−)/
Beta2AR(+) and HK2(−)/Beta2AR(−) HCC patients. De-
tecting HK2 and Beta2AR expression in HCC simultan-
eously has clinical significance in prognosis prediction.
However, there are some limitations of our study. Firstly,
the sample number of our study is not very large, which
could attenuate the statistical power. Secondly, because
of the limitations of pathologic samples, only immuno-
histochemistry was employed in our study, other
Fig. 4 The difference of live time among different groups. One-way
ANOVA analysis shows that survival time of HK2(−)/Beta2AR(−) is longer
than that of HK2(−)/Beta2AR(+) and HK2(+)/Beta2AR(+) significantly. The
survival time of HK2(−)/Beta2AR(+) is also longer than that of HK2(+)/
Beta2AR(+). Data are shown with mean ± SD. ## P< 0.0001 vs. HK2(+)/
Beta2(+) group, ** P< 0.0001 vs. HK2(−)/Beta2(+) group, #P= 0.001 vs.
HK2(+)/Beta2AR(+) group
Zhang et al. BMC Gastroenterology  (2016) 16:57 Page 8 of 10
methods to detect HK2 and Beta2AR (Western blot and
quantitative real time PCR) are needed to confirm the
results of this study. Moreover, in vitro studies are also
required to prove these findings. Thirdly, we were not
able to calculate the score of Child Pugh due to incom-
plete information collection, the effect of liver function
reservoir on HCC survival and Cox regression analyses
could not be evaluated. Fourthly, we were unable to re-
trieved the recurrence information of HCC, so we did
not evaluate the expression of HK2 and Beta2AR on the
recurrence of HCC. Despite of the above limitations, our
study will shed new light on HCC treatment and prog-
nosis predictions.
Conclusion
In summary, Beta2AR and HK2 expression in HCC tis-
sues is positively correlated. High expression of HK2
and beta2AR in HCC can predict prognosis of HCC pa-
tients independently and synergistically. Beta2AR might
increase the grade of malignancy of HCC via promoting
HK2 expression. Combined targeting of HK2 and
Beta2AR might be a promising therapy for HCC.
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